Table 1.
Characters for non-cancer participants in nine placebo-controlled and standard care-controlled statin trials
| Study | Year | Number of participants | Type | Mean follow-up (years) | Age (years) | Statin | Jadad Score |
|---|---|---|---|---|---|---|---|
| HPS | 2011 | 20536 | At increased risk of vascular events | 16.3 | 40–80 | simvastatin 40 mg | 5 |
| AURORA | 2009 | 2773 | With maintenance hemodialysis | 3.2 | 50–80 | rosuvastatin 10 mg | 5 |
| CARDS | 2008 | 2838 | With type 2 diabetes and no history of coronary heart disease (CHD) | 3.9 | 40–75 | atorvastatin 10 mg | 4 |
| JUPITER | 2008 | 17802 | Healthy | 1.9 | 50 years and older | rosuvastatin 20 mg | 6 |
| GDDS | 2005 | 1255 | With type 2 diabetes receiving maintenance hemodialysis | 4 | 18–80 | atorvastatin 20 mg | 7 |
| ALLIANCE | 2004 | 2442 | CHD patients with hyperlipidemia | 4.3 | 61.1(atorvastotin)/61.3(usual-care) | a maximum atorvastatin dose of 80 mg/day | 3 |
| PROSPER | 2002 | 5804 | With a history of, or risk factors for, vascular disease | 3.2 | 70–82 | pravastatin 40 mg | 6 |
| LIPS | 2002 | 1677 | After successful first percutaneous coronary intervention (PCI) |
3.9 | 18–80 | fluvastatin 80 mg | 6 |
| 4S | 1994 | 4444 | With CHD | 5.4 | 35–70 | simvastatin 20 mg | 5 |